Should You Buy Sangamo Therapeutics Inc (SGMO) Today? Analysis, Price Targets, and 2026 Outlook.
No data
No data
Growth
Profitability
Efficiency
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 3.75 USD with a low forecast of 1 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast SGMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGMO is 3.75 USD with a low forecast of 1 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
Current: 0.353
Low
1
Averages
3.75
High
10
Current: 0.353
Low
1
Averages
3.75
High
10
Barclays
Overweight -> Equal Weight
downgrade
$5 -> $1
AI Analysis
2025-11-07
Reason
Barclays
Price Target
$5 -> $1
AI Analysis
2025-11-07
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Sangamo to Equal Weight from Overweight with a price target of $1, down from $5. The company's Q3 report highlighted the FDA's reaffirmation of an accelerated approval path using eGFR slope as the endpoint and its cash runway has been extended into Q1 of 2026, the analyst tells investors in a research note. Barclays steps to the sidelines pending further clarity on a Fabry deal.
Barclays
Overweight
downgrade
$9 -> $5
2025-05-14
Reason
Barclays
Price Target
$9 -> $5
2025-05-14
downgrade
Overweight
Reason
Barclays lowered the firm's price target on Sangamo to $5 from $9 and keeps an Overweight rating on the shares. The company's Q1 call provided additional color on cash runway extended into late Q3 by the capital raise, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGMO
